Our company benefits from the expertise and experience of numerous advisors, including world-renowned experts in diabetes drug development, professors, hypoglycemia experts, respected researchers, and dedicated patient advocates.
Kelly Close, MBA
Kelly is a recognized global authority on diabetes and obesity markets and a prominent patient advocate. Kelly is a cofounder and President of Close Concerns, a highly acclaimed healthcare information company focused exclusively on diabetes and obesity. Kelly is the author of numerous peer-reviewed manuscripts and was recognized in 2012 by the American Diabetes Association with the Excellence in Health Communications award. Kelly serves on the board of several nonprofit diabetes-related organizations.
Alexander Fleming, MD
Dr. Fleming is a board-certified endocrinologist and highly recognized authority in the metabolic and endocrine space with extensive FDA experience. He served 12 years as FDA Supervisory Medical Officer for diabetes and endocrine disorders. At FDA, he led reviews for the earliest biotech products, the first statin, insulin analogs, metformin, and many other important drugs. Dr. Fleming is the CEO of Kinexum, a drug development consulting firm.
Brian Frier, MD
Professor Frier is an internationally recognized expert in hypoglycemia. He has over 30 years experience in clinical diabetes and research and is Honorary Professor of Diabetes of the University of Edinburgh. His principal research interest is the pathophysiology of diabetic hypoglycemia. He has published extensively and coedited two reference textbooks on hypoglycemia. He is Editor-in-Chief of an open-access, online e-journal, Diabetic Hypoglycemia.
Antonio Pontiroli, MD
Dr. Pontiroli is the Chair of Internal Medicine at the University of Milan, Italy. His research interests include the pathophysiology and treatment of diabetes and obesity. Dr. Pontiroli was the first to publish on intranasal delivery of glucagon.
Elizabeth Seaquist, MD
Dr. Seaquist is Professor of Medicine and Pennock Family Chair in Diabetes Research at the University of Minnesota. Her research interests include the effects of hypoglycemia on brain metabolism, structure, and function. Dr. Seaquist is a principal investigator in several large multinational clinical studies in diabetes and served as the 2014 President of Medicine and Science of the American Diabetes Association.
William Tamborlane, MD
Dr. Tamborlane is one of the most highly regarded clinical scientists in childhood diabetes. He serves as the Deputy Director for Clinical Research at the Yale Center for Clinical Investigation at the Yale School of Medicine. He has devoted his academic career to patient-oriented research in diabetes pathophysiology and therapeutics. His major contributions include pioneering studies in the development of insulin pump therapy, investigations of diabetes-induced defects in counter-regulatory hormone responses to hypoglycemia, and demonstration of the role of insulin resistance in pediatric metabolic disorders.
Hope Warshaw, MMSc, RD, CDE, BC-ADM, is a dietitian and diabetes educator with 35 years in practice. She operates Hope Warshaw Associates, LLC, a consulting practice in Washington, DC. Her work today spans from corporate consulting to consumer and professional writing and diabetes and weight management counseling. Hope has authored or co-authored numerous books for practitioners and consumers on diabetes nutrition management published by American Diabetes Association and writes regularly for Diabetic Living magazine. Hope is serving as the 2015 President-elect of the American Association of Diabetes Educators.
Jean-Francois Yale, MD
Dr. Yale is Professor of Endocrinology at McGill University in Montreal, Canada. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992 to 1994 and chaired the Expert Committee that published the 2001 Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Hypoglycemia in Diabetes. His research interests include the prevention of hypoglycemia and intensive management of diabetes, and he has participated in numerous multicenter trials on new therapies for type 1 and type 2 diabetes.